AI Article Synopsis

  • Glioblastoma (GBM) is a highly aggressive brain tumor linked to cancer stem cells, which contribute to its recurring nature.
  • The study found that human GBM cells exhibiting stemness showed greater sensitivity to natural killer (NK) cells compared to non-stemness cells, particularly in a specific culture condition (NBE).
  • Results indicated that the NBE GBM cells had higher NK cell cytotoxicity and altered expression of NKG2D ligands, suggesting that immune modulation could be a useful complementary treatment for challenging cases of GBM.

Article Abstract

Background: Glioblastoma (GBM) is one of the most lethal tumors with a poor prognosis. Its inevitable recurrence is frequently explained by the presence of cancer stem cells. We aimed to show that human GBM cells with stemness features are more sensitive to natural killer (NK) cells than GBM cells without stemness characteristics.

Methods: Natural killer cell cytotoxicity was measured using flow cytometry in neurosphere-forming U87 GBM cells cultured with neurobasal media (NBE condition) and compared with that in serum-cultured U87 GBM cells (serum condition). Cytotoxicity was examined after addition of blocking NKG2D monoclonal antibodies. The expression profile of NK ligands of NK cells were investigated by reverse transcription polymerase chain reaction and western blot analysis in the U87 GBM cells in both conditions.

Results: NBE U87 cells showed higher cytotoxicity to NK cells than serum U87 cells did (55 vs 35% at an effector to target cell ratio of 5:1). The increased cytotoxicity was diminished in NBE U87 cells by a larger gap than in serum U87 cells by adding NKG2D blocking antibodies. Of the NKG2D ligands, the expression of ULBP1 and ULBP3 was relatively increased in NBE U87 cells compared to serum U87 cells.

Conclusions: U87 GBM cells with stemness features demonstrate increased cytotoxicity to NK cells in association with altered NKG2D ligand expression of NK cell activating receptor. Applying immune modulation to GBM treatment may be a promising adjuvant therapy in patients with intractable GBM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303255PMC
http://dx.doi.org/10.1186/s12935-017-0397-7DOI Listing

Publication Analysis

Top Keywords

gbm cells
24
u87 cells
20
cells
17
cells stemness
16
u87 gbm
16
stemness features
12
natural killer
12
nbe u87
12
serum u87
12
u87
10

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!